Allergies come in all shapes and sizes ...
Just like allergy sufferers. And they are on the rise. For many people allergies can range from sniffling and sneezing to skin rashes to gastrointestinal issues. A certain percentage, however, have more than these uncomfortable symptoms to deal with. Anaphylaxis, a serious life-threatening reaction, causes approximately 1,500 deaths a year in the United States alone. Clearly, allergies are nothing to sneeze at!
Articles for Advocacy
Good news! DBV Technologies is preparing to resubmit their application to the Food and Drug Administration (FDA) for a new treatment for peanut allergies in children called Viaskin Peanut, better known as the peanut patch. The company has obtained Fast Track and Breakthrough Therapy designation from the FDA and is planning to submit by the third quarter of this year, a faster than expected timeframe. Meanwhile, rival Aimmune Therapeutics has already submitted their application and may win U.S. approval for its drug ahead of DBV.
DBV Technologies Sets Sights on FDA Resubmission for Peanut Allergy Treatment
By Ned Pagliarulo
Feb. 14, 2019
Dive Brief:
DBV Technologies expects to resubmit its experimental treatment for peanut allergy to the Food and Drug Administration by the third quarter of this year, a speedier-than-expected path back to the regulator after the company withdrew its original application last December.
No one particularly likes needles, including the person administering them and the person receiving medication with them—even in an emergency. So we are pleased to report efforts are being made to develop a dry powder nasal spray of epinephrine to treat anaphylaxis. The Food and Drug Administration (FDA) has already stated that nasal delivery can be an excellent alternative for delivery of rescue medications during life threatening patient events, such as drug overdoses.
StellaPharma to Develop Epinephrine Nasal Spray Product
News provided by
StellaPharma, Inc.
Jan 15, 2019
RALEIGH, N.C.
PRNewswire
StellaPharma, Inc. (Stella) announced today that it has entered into an agreement whereby Stella will acquire the assets of G2B Pharma (G2B) including IP related to a dry powder nasal formulation of epinephrine being developed for anaphylaxis. Recent U.S. FDA product approvals indicate nasal delivery can be an excellent alternative route for delivery of rescue medications during life threatening patient events.
Raleigh, North Carolina based StellaPharma was founded in 2018 by three pharmaceutical industry executives that are focused on developing therapeutic products that address unmet patient needs. Nasally delivered dry powder epinephrine, if approved by U.S. FDA, may provide a much needed and much desired alternative to epinephrine auto-injectors. Stella's executives include Steve Stefano, Executive Chairman, Thomas Parker, SVP Operations and Ted Lanpher, SVP Business Strategy. Stefano is a former 29-year GSK executive that led GSK's U.S. Payer Markets and Neurohealth Division by growing top-line revenues from $300 million to $2.5 billion. Parker and Lanpher are experienced industry veterans having developed and commercialized a range of allergy-related pharmaceutical products and services.
One measure of the increasing number of allergies in the U.S. is how many health insurance claims have been filed for anaphylaxis food reactions. A recent study showed that claims rose a whopping 377% from 2007 to 2016! The Food Allergy Research & Education (FARE) group recently launched the Contains: Courage™ campaign, to drive awareness and raise an unprecedented amount of funding for research, therapies and diagnostics to improve the quality of life of children and adults who are affected.
Food Allergy-Related Insurance Claims Up in Almost Every State in the Country
By News Wire
January 23rd, 2019
McLean, VA – Food Allergy Research & Education (FARE), the largest private funder of food allergy research in the world, today released the results of a study on private insurance claim lines and food allergies. The study showed that claim lines with diagnoses of anaphylactic food reactions rose 377% from 2007 to 2016, and in every state except Massachusetts, claim lines with anaphylactic food reactions and history of food allergy diagnoses represented an increasing share of all medical claim lines from 2009 to 2016. Anaphylaxis is a serious allergic reaction that can occur quickly and is potentially life-threatening.
Upcoming Events
April 1, 2019 - ANAPHYLAXIS EMERGENCY TRAINING SEMINAR
April 1, 2019 - Anaphylaxis Emergency Training Seminar
University of Rochester
School of Nursing
Helen Wood Hall Auditorium
Crittenden Blvd
Rochester, NY 14642
Monday, April 1st, 2019 7pm
RSVP to This email address is being protected from spambots. You need JavaScript enabled to view it.
or call 585-255-0384
FREE admission!
Location - Auditorium
Presenter - Kirsi-Jarvinen-Seppo, MD
Audience - nursing students, medical center staff, security staff, etc.
Parking - paid lot adjacent to Hall in front of CTSB building